Skip to main content
Clinical Trials/NCT03818841
NCT03818841
Unknown
Not Applicable

High-flow Nasal Cannula Therapy in the Treatment of Acute Carbon Monoxide Poisoning

Università degli Studi del Piemonte Orientale "Amedeo Avogadro"1 site in 1 country96 target enrollmentFebruary 1, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Carbon Monoxide Poisoning
Sponsor
Università degli Studi del Piemonte Orientale "Amedeo Avogadro"
Enrollment
96
Locations
1
Primary Endpoint
COHb reduction at 90 minutes
Last Updated
7 years ago

Overview

Brief Summary

The aim of the study is to test whether oxygen therapy delivered through high-flow nasal cannula devices in patients admitted to the emergency department for acute carbon monoxide poisoning is superior to the non-rebreathing oxygen face mask therapy with a 15 L/minute oxygen flow (currently the first-line therapy), in terms of reduction of carboxyhemoglobin (COHb) concentration and delayed neurological sequelae incidence.

Registry
clinicaltrials.gov
Start Date
February 1, 2019
End Date
February 1, 2022
Last Updated
7 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Università degli Studi del Piemonte Orientale "Amedeo Avogadro"
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age v 18 years
  • Carbon monoxide intoxication as major problem leading to emergency department admission
  • Carboxyhemoglobin (COHb) concentration 10% at the time of enrolment

Exclusion Criteria

  • Age \< 18 years
  • Glasgow coma scale ≤ 13
  • Refusal to give consent

Outcomes

Primary Outcomes

COHb reduction at 90 minutes

Time Frame: 90 minutes

Patients in the High-flow nasal cannula group and patients in the non-rebreathing oxygen mask group will be compared in terms of COHb reduction at 90 minutes. The hypothesis is that in patients treated with high flow nasal cannula the reduction in COHb at 90 minutes will be significantly different compared to patients treated with non-rebreathing oxygen mask.

Secondary Outcomes

  • Variation in the incidence of delayed neurologic sequelae(6 weeks)
  • Variation in serum lactate concentration(6 weeks)
  • Variation in serum troponin concentration(6 weeks)
  • Variation in S100B levels concentration(6 weeks)

Study Sites (1)

Loading locations...

Similar Trials